02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
22:55 , May 19, 2017 |  BioCentury  |  Strategy

Full set in hemophilia

Pfizer Inc. ’s deal with Sangamo Therapeutics Inc. brings in what the pharma believes is the last of three mechanisms it needs to cover the hemophilia population with new non-factor replacement therapies. The companies announced...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

BeneFIX: Phase III data

Top-line data from an open-label, international Phase III trial in 25 patients with moderately severe to severe hemophilia B showed that once-weekly 100 IU/kg BeneFIX as prophylaxis met the primary endpoint of reducing median ABR...
00:55 , Jul 17, 2014 |  BC Extra  |  Clinical News

PFE's BeneFIX as prophylaxis bests on-demand in hemophilia B

Pfizer Inc. (NYSE:PFE) said BeneFIX as prophylaxis met the primary endpoint of reducing median annualized bleeding rate (ABR) vs. on-demand treatment with BeneFIX in a Phase III trial evaluating continuous prophylactic treatment of bleeding in...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Pfizer, World Federation of Hemophilia (WFH) hematology news

Pfizer is donating more than 35 million IUs of recombinant Factor IX therapy to the non-profit to help hemophilia B patients in underserved regions of the world. The WFH is a network of patient organizations...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Clinical News

Long Acting rFactor lX: Phase III data

Top-line data from the open-label, international Phase III B-LONG trial in 123 evaluable previously treated hemophilia B patients aged 12 and older showed that rFIXFc as prophylaxis met the primary efficacy and safety endpoints. To...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Pfizer, Takeda sales and marketing update

Effective on Dec. 31, 2012, Takeda and Pfizer will end a Japanese distribution deal for Pfizer's products. Takeda will stop selling 13 products, but will continue to market pneumococcus vaccine Prevenar for infants and young...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum, Pfizer sales and marketing update

Swedish Orphan returned co-promotion rights in the Nordic region to Pfizer for hemophilia A drug ReFacto AF moroctocog alfa and hemophilia B drug BeneFIX . Swedish Orphan will receive $47.5 million for the return of...
08:00 , Feb 20, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) gained $0.21 (27%) to $0.97 on Wednesday after FDA approved an NDA from partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) for Bio-T-Gel to treat male hypogonadism. BioSante is eligible for...
01:40 , Feb 17, 2012 |  BC Extra  |  Company News

SOBI returns co-promote rights for hemophilia drugs to Pfizer

Swedish Orphan Biovitrum AB (SSE:SOBI) returned co-promotion rights in the Nordic region to Pfizer Inc. (NYSE:PFE) for hemophilia A drug ReFacto AF moroctocog alfa and hemophilia B drug BeneFIX . Swedish Orphan will receive $47.5...